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Background: The hepatocyte growth factor receptor gene
(MET) exon 14 skipping (METex14) has recently been
described a potential driver alteration in lung cancer
targetable by mesenchymal-to-epithelial transition factor
(MET) tyrosine kinase inhibitors (TKIs).
Methods: Well-validated hybrid capture–based compre-
hensive genomic proﬁling was performed at the request of
individual treating physicians.
Results: Of 11,205 lung cancers proﬁled by comprehensive
genomic proﬁling, 298 (2.7%) carcinomas harbored alter-
ations predicted to cause METex14, including adenosqu-
amous (8.2%), sarcomatoid (7.7%), histologic subtype not
otherwise speciﬁed (3.0%), adenocarcinoma (2.9%), squa-
mous cell (2.1%), large cell (0.8%), and SCLC (0.2%). Acinar
features were present in 24% of the METex14 samples. Six
cases (2%) harbored MET Y1003X mutations affecting
binding of the MET-negative regulator, E3 ubiquitin protein
ligase. The median age of all patients with METex14 was 73
years (range 43–95) and 60% were female. Concurrent,
murine double minute gene (MDM2) ampliﬁcation, cyclin-
dependent kinase 4 gene (CDK4) ampliﬁcation, and EGFR
ampliﬁcation were observed in 35%, 21%, and 6.4% of
patients with METex14, respectively. KRAS mutation was
observed in 3% of cases. Concurrent MET ampliﬁcation
(METamp) (median copy number 10) was identiﬁed in
15% of METex14 samples. Signiﬁcant differences in tumormutational burden and type of the METex14 alterations
were observed between the METamp and non-METamp
samples. Response to MET TKI was observed in both in
patients with METamp and in patients without METamp
METex14.
Conclusion: Diverse targetable METex14 alterations were
identiﬁed in patients with NSCLC across age groups,
including elderly patients, and in all major NSCLC histologic
subtypes with an overall frequency of 2.7%. These ﬁndings
support the use of hybrid capture–based molecular proﬁlingJournal of Thoracic Oncology Vol. 11 No. 9: 1493-1502
1494 Schrock et al Journal of Thoracic Oncology Vol. 11 No. 9across NSCLC subtypes to identify patients who will poten-
tially beneﬁt from MET TKIs.
 2016 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Genomic proﬁlingIntroduction
Tremendous advances have been achieved in the past
decade in identifying druggable genomic drivers, in-
cluding activating mutations of EGFR and BRAF, as well
as fusions of the kinases anaplastic lymphoma receptor
tyrosine kinase gene (ALK), ROS1, ret proto-oncogene
(RET), and neurotrophic tyrosine kinase, receptor, type 1
gene (NTRK) in a signiﬁcant fraction of patients with
NSCLC.1,2 The mesenchymal-to-epithelial transition factor
(MET) receptor tyrosine kinase is a critical regulator of cell
growth and development. Aberrant activation of MET in
cancer can occur through several mechanisms, including
hepatocyte growth factor receptor gene (MET) ampliﬁca-
tion (METamp) or rearrangement, protein overexpression,
overexpression of its ligand hepatocyte growth factor, and
activating point mutations.3,4 The multitargeted MET
tyrosine kinase inhibitors (TKIs) crizotinib and cabo-
zantinib have been approved for treatment of ALK-rear-
ranged NSCLC and medullary and well-differentiated
thyroid cancer, respectively.5,6 Recently, two large-scale
randomized phase 3 clinical trials with MET TKIs in un-
selected NSCLC have been unsuccessful.7,8 However, these
studies did not utilize METamp or expression as entry
criteria. Hence, a clear base of evidence for effective direct
targeting of MET activation in solid malignancies remains
elusive.
MET exon 14 alterations at RNA splice acceptor or
donor sites have been recently described as a distinct
mechanism of MET activation, leading to MET exon 14
skipping (METex14) and disruption of a DpYR motif,
including Y1003, required for efﬁcient binding of E3
ubiquitin protein ligase (CBL). These alterations have been
shown to lead to increased MET stability and oncogenic
potential, and to confer sensitivity to crizotinib.9–14 Addi-
tionally, small series have demonstrated that patients with
NSCLC harboring METex14 alterations beneﬁt from MET
TKIs.15,16 Recently we performed a large-scale analysis of
METex14 alterations in multiple cancers and found that
these alterations are most common in lung adenocarci-
nomas (3%) and in other malignant lung neoplasms
(2.3%).17 Here we expand on that series to include morethan 100 additional patients with lung cancer with
METex14 alterations and comprehensively characterize
these cases by patient characteristics, tumor pathology,
mutational burden, and coampliﬁcation of MET, murine
double minute gene (MDM2), and EGFR. We additionally
present eight previously unpublished responses to tar-
geted therapy.Methods
DNA was extracted from 40-mm formalin-ﬁxed
parafﬁn-embedded sections, and comprehensive
genomic proﬁling (CGP) was performed on hybridization-
captured, adaptor ligation–based libraries to a mean
coverage depth of 820 for at least 3769 exons of 236
cancer-related genes plus 47 introns from 19 genes
frequently rearranged in cancer. CGP for 11,205 consec-
utive lung cancers was ordered as part of routine clinical
practice (August 2012–November 2015). Age, sex, stage,
and histologic subtype were abstracted from the
accompanying pathology report submitted by the treat-
ing physician. A subspecialty board–certiﬁed thoracic
pathologist reviewed all METex14-positive cases. Testing
was performed in a Clinical Laboratory Improvement
Amendments–certiﬁed, College of American Pathologists–
accredited reference laboratory (Foundation Medicine,
Inc., Cambridge, MA). Patient samples were evaluated
for genomic alterations (GAs), including base pair
substitutions, insertions/deletions (indels), copy num-
ber alterations, and rearrangements, as described pre-
viously.18 These GAs were then manually inspected to
identify those likely to affect splicing of MET exon 14, or
to delete the exon entirely as described previously.17
Focal ampliﬁcations were called at segments with six
or more copies (or 7 for triploid and 8 for tetraploid
tumors) in samples with a purity greater than 20%.
Tumormutational burden (TMB)was characterized as
the number of somatic base substitution or indel alter-
ations per megabase (MB) after ﬁltering to remove
known somatic and deleterious mutations. To calculate
TMB, we used a novel algorithm that quantiﬁed the
number of somatic mutations detected and extrapolated
that value to the exome or genome as a whole (Frampton
et al., Foundation Medicine Inc., unpublished data). Al-
terations with known (occurring as known somatic al-
terations in the Catalogue of Somatic Mutations in Cancer
database) and likely (truncations in tumor suppressor
genes) functional status were not counted. This ﬁltering
was performed to avoid upward skewing of mutational
burden because CGP preferentially proﬁles genes known
to be recurrently mutated in cancer. To calculate the
mutation burden per MB, the total number of mutations
was divided by the coding region target territory of the
test, which is 1.11 MB for the current version. Ordinal
September 2016 MET Exon 14–Mutated Lung Cancers 1495relationships were examined using the Mann-Whitney U
test; categorical relationships were examined using
Pearson’s chi-squared test with Yates’s continuity
correction applied when applicable. Approval for this
study, including a waiver of informed consent and a
Health Insurance Portability and Accountability Act
waiver of authorization, was obtained from the Western
Institutional Review Board (Protocol No. 20152817).Results
Clinical and Molecular Characteristics
Using CGP in the course of clinical care, we assayed
tumor specimens from 11,205 patients with lung cancer
(Supplementary Table 1). We identiﬁed METex14 alter-
ations in 298 patients (2.7%). The median age of patients
withMETex14 was 73 years (range 47–95), with 79% age
65 years or older. The available clinical and molecular
characteristics of all 298 patients are listed in Table 1.
METex14 alterations were most common in the adenos-
quamous histologic subtype (8.2%), followed by in the
sarcomatoid histologic subtype (7.7%), not otherwise
speciﬁed subtypes (3.0%), adenocarcinoma (2.9%), squa-
mous cell carcinoma (2.1%), and large cell carcinoma
(0.8%, two of 243) (Supplementary Fig. 1, Table 1).
Through internal review of available hematoxylin and
eosin–slides sarcomatoid features were identiﬁed in 17
additional METex14 cases (Supplementary Fig. 2), and
most (59%) of the not otherwise speciﬁed METex14 sam-
ples favored adenocarcinoma. There was no notable dif-
ference in the types of METex14 alterations among the
various histologic subtypes. Patients with squamous and
adenosquamous carcinoma had a slighter lower median
age relative to the patients with METex14 and other his-
tologic subtypes (p ¼ 0.029). Acinar features were identi-
ﬁed in 23.8% of cases, followed by solid component
(21.4%), micropapillary (9.7%), papillary (8.1%), and
lepidic features (5.4%). Signet ring featureswere identiﬁed
in four cases (1.3%), all of which were adenocarcinomas.
In the 298 cases with METex14 alterations analyzed,
165 different variants predicted to affect MET exon 14
were detected. These included 157 base substitutions (24
unique) and 145 indels (139 unique), and they affected
the splice acceptor site in 104 cases, the splice donor site
in 191 cases, and the approximately 25–base pair (bp)
intronic noncoding region immediately adjacent to the
splice acceptor site in seven cases (Table 1 and Fig. 1).
Five cases harbored multiple METex14 alterations
(Supplementary Table 2). In terms of the type ofMETex14
alterations, 51.6% were base substitutions and 47.7%
were indels. We also detected two cases with whole exon
deletions ofMET exon 14. Six cases of mutations affecting
Y1003, which have been reported to impair CBL binding
and MET degradation, and in one case leading toMETex14, were identiﬁed.19–21 All six of these patients
were elderly females (Supplementary Table 3). In addi-
tion to the METex14 alterations characterized in this se-
ries, we observed two cases with MET R1004G mutation.
Similar to alteration of Y1003, mutations at D1002 and
R1004 have been shown to disrupt CBL binding and MET
degradation, and they may also be clinically relevant.19
Concurrent METamp
Concurrent MET ampliﬁcation (METamp) (mean copy
number ¼ 13 [range 6–59], median ¼ 10) was detected in
44 cases (14.8%). This represents enrichment as compared
with in the lung cancer cases inourdata set that didnot have
METex14 alterations, in which METamp was observed in
approximately 2.5% of cases. There was no signiﬁcant
difference in median age, sex, smoking history, or stage
between the patients with METex14 with or without con-
current METamp (Table 2). However, the type of METex14
alterations (p ¼ 0.017) and TMB distribution (p ¼ 0.013)
were signiﬁcantly different between patientswithMETex14
with or without concurrent METamp (Table 2). Non-MET-
amp cases were most often characterized by a low muta-
tional burden (zero to ﬁve mutations per MB), whereas
METamp cases were most often characterized by an inter-
mediate low mutational burden (six to 10 mutations per
MB) (Table 2). The median number of mutations per MB
was 4.4 for non-METamp and 6.8 forMETamp (p¼ 0.007).
Other Concurrent Driver Mutations
MDM2 ampliﬁcation (MDM2amp) (mean copy
number ¼ 16 [range 6–100], median ¼ 15) and cyclin-
dependent kinase 4 gene (CDK4) ampliﬁcation
(CDK4amp) (mean copy number ¼ 14 [range 6–54],
median ¼ 14), which have been previously shown to
frequently co-occur withMETex14 alterations,17 were also
found in 103 cases (34.6%) and 63 cases (21.1%),
respectively. There was no signiﬁcant difference in most
available characteristics between patients with and
without MDM2amp (Supplementary Table 4). However,
CDK4amp signiﬁcantly correlated with MDM2amp in this
series (SupplementaryTable4). Interestingly,we identiﬁed
concurrent EGFR ampliﬁcation (mean copy number ¼ 11
[range 7–16],median¼10) among 6.4% ofMETex14 cases;
erb-b2 receptor tyrosine kinase 2 gene (ERBB2) ampliﬁ-
cation and KRASmutation were present in two (0.7%) and
nine (3%) cases, respectively. Therewas oneMETex14 case
each with EGFR mutation (G719A), BRAF mutation
(G466V), and concurrent echinoderm microtubule associ-
ated protein like 4 gene (EML4)-ALK fusion respectively.
TMB and Smoking Status
The average TMB in cases with METex14 alterations
was 6.9 mutations per MB (range zero to 197.9), which is
Table 1. Clinical and Molecular Characteristics of NSCLC Harboring METex14 Alterations by Histologic Subtype
Patient Data Values
Total Cases
All AdenoCA NOS SqCC AdenoSqCC Sarcomatoid
11,205 7140 1659 1206 98 104
Cases with METex14 alteration, n (%)a 298 (2.7) 205 (2.8) 49 (3.0) 25 (2.1) 8 (8.2) 8 (7.7)
Median age (range), y 72 (47–95) 73 (47–95) 75 (51–92) 69 (51–92) 67 (47–79) 75 (68–83)
Age, n (%)
<age 65 y 61 (20) 46 (22) 6 (12) 7 (28) 2 (25) 0
age 65 y 235 (79) 157 (77) 43 (88) 18 (72) 6 (75) 8 (100)
Unknown 2 (0.7) 2 (1) 0 0 0 0
Sex, n (%)
Male 118 (39.6) 79 (39) 19 (39) 10 (40) 4 (50) 4 (50)
Female 180 (60.4) 126 (61) 30 (61) 15 (60) 4 (50) 4 (50)
Smoking history, n (%)
Yes 11 (5.4) 5 (2) 4 (8) 1 (4) 0 1 (12)
No 25 (8.4) 18 (9) 3 (6) 4 (16) 0 0
Unknown 262 (87.9) 182 (89) 42 (86) 20 (80) 8 (100) 7 (88)
Differentiation, n (%)
Good 16 (9.9) 15 (7) 0 1 (4) 0 0
Moderate 38 (12.8) 32 (16) 2 (4) 1 (4) 3 (38) 0
Poor 107 (35.9) 58 (28) 27 (49) 13 (52) 3 (38) 4 (50)
Unknown 137 (46.0) 100 (49) 20 (41) 10 (40) 2 (25) 4 (50)
Histologic subtype, n (%)
Adenocarcinoma 205 (68.8) — — — — —
Adenosquamous 8 (2.7) — — — — —
Squamous 25 (8.4) — — — — —
Large cell 2 (0.7) — — — — —
Sarcomatoid 8 (2.7) — — — — —
SCLC 1 (0.3) — — — — —
NSCLC (NOS) 49 (16.4) — — — — —
Stage, n (%)
I 12 (4.0) 10 (5) 1 (2) 0 1 (12) 0
II 27 (9.1) 19 (9) 2 (4) 4 (16) 1 (12) 0
III 15 (5.0) 7 (3) 4 (8) 2 (8) 0 2 (25)
IV 175 (58.7) 118 (58) 34 (69) 15 (60) 4 (50) 3 (38)
Unknown 69 (23.2) 51 (25) 8 (16) 4 (16) 2 (25) 3 (38)
METex14 alterations, n (%)b
Base substitution splice donor 149 (49.1) 103 (50) 24 (49) 15 (60) 3 (38) 3 (38)
Indel splice acceptor 100 (32.9) 71 (35) 18 (37) 5 (20) 4 (50) 1 (12)
Indel splice donor 42 (13.8) 28 (14) 4 (8) 4 (16) 1 (12) 4 (50)
Base substitution splice acceptor 4 (1.3) 3 (1) 0 1 (4) 0 0
Base substitution noncoding
adjacent splice acceptor
4 (1.3) 2 (1) 2 (4) 0 0 0
Indel noncoding adjacent splice acceptor 3 (1.0) 2 (1) 1 (2) 0 0 0
Whole exon 14 deletion 2 (0.7) 1 (0.5) 1 (2) 0 0 0
Concurrent MET ampliﬁcation, n (%)
Yes 44 (14.8) 32 (16) 9 (23) 2 (8) 0 1 (13)
No 254 (85.2) 173 (84) 40 (67) 23 (92) 8 (100) 7 (87)
Concurrent MDM2 ampliﬁcation, n (%)
Yes 103 (34.6) 79 (39) 13 (27) 6 (36) 5 (63) 0
No 195 (65.4) 126 (61) 36 (73) 19 (64) 3 (37) 8 (100)
Concurrent CDK4 ampliﬁcation, n (%)
Yes 63 (21.1) 50 (24) 9 (23) 2 (8) 1 (13) 0
No 235 (78.9) 155 (76) 40 (67) 23 (92) 7 (87) 8 (100)
Concurrent EGFR ampliﬁcation, n (%)
Yes 19 (6.4) 13 (6) 4 (8) 0 0 2 (25)
No 279 (93.6) 192 (94) 45 (92) 25 (100) 8 (100) 6 (75)
(continued)




All AdenoCA NOS SqCC AdenoSqCC Sarcomatoid
11,205 7140 1659 1206 98 104
Mutational load (mutations per MB), n (%)
Low (0–5) 168 (56.4) 117 (57) 27 (55) 13 (52) 5 (63) 4 (50)
Intermediate low (6–10) 95 (31.9) 63 (31) 16 (33) 9 (36) 3 (38) 3 (38)
Intermediate high (11–20) 31 (10.4) 21 (10) 6 (12) 3 (12) 0 1 (13)
High (>20) 4 (1.3) 4 (2) 0 0 0 0
aPercentage calculated from number in previous row.
bIncludes four cases with two different METex14 alterations and one case with three different METex14 alterations (see Supplementary Table 2).
METex14, hepatocyte growth factor receptor gene exon 14 skipping; AdenoCA, adenocarcinoma; NOS, not otherwise speciﬁed; SqCC, squamous cell carcinoma;
AdenoSqCC, adenosquamous carcinoma; Indel: insertion/deletion; MDM2, murine double minute 2 gene; CDK4, cyclin-dependent kinase 4 gene; MB,
megabase.
September 2016 MET Exon 14–Mutated Lung Cancers 1497slightly lower than the overall average of 10.7 mutations
per MB for all lung cancers in our database. More
importantly, most (56.4%) of the METex14 tumor sam-
ples had low TMB (zero to ﬁve mutations per MB), and
this was true regardless of histologic subtype (Table 1).
Additionally, we assessed the relationship between
smoking status and TMB. Smoking history was available
for 36 of 298 patients. Among the 25 never-smokers, the
mean TMB was 4.5 mutations per MB (range zero toFigure 1. Schematic of all the genomic positions of hepatocyte g
Alterations included base substitutions and insertions/deletions a
and Y1003mutation. Genomic positions with alterations occurring
and the number of cases is greater than two. An octothorp (#) in13.2, median ¼ 3.3), whereas the mean TMB for the 11
patients with a history of smoking was 25.4 mutations
per MB (range 0.8–197.7, median ¼ 10.4).
Response of Patients with METex14 NSCLC to
MET TKIs
Treatment outcomes were available for eight previ-
ously unpublished METex14 cases treated with crizotinib.
All eight patients in these cases experienced diseaserowth factor receptor gene (MET) exon 14 skipping alterations.
t the splice donor and acceptor sites, whole exon 14 deletion,
inmore than one case are indicatedwith an asterisk (*) for two
dicates samples with whole exon deletion of exon 14.
Table 2. Comparison of Clinical and Molecular Characteristics of Patients with METex14 NSCLC with or without Concurrent
MET Ampliﬁcation
Patient Data Without MET Ampliﬁcation With MET Ampliﬁcation p Value
No. patients 254 44 —
Median age (range), y 73 (47–95) 72 (49–87) 0.475
Sex, n (%) 0.353
Male 103 (41) 14 (32)
Female 151 (59) 30 (68)
Smoking history, n (%) 0.106
Yes 7 (3) 4 (9)
No 23 (9) 2 (5)
Unknown 224 (88) 38 (85)
Histologic subtype, n (%) <0.001
Adenocarcinoma 173 (68) 32 (73)
Adenosquamous 8 (3) 0
Squamous 23 (9) 2 (5)
Large cell 2 (1) 0
Sarcomatoid 7 (3) 1 (2)
SCLC 1 (0.4) 0
NSCLC (NOS) 40 (16) 9 (20)
Differentiation, n (%) 0.046
Good 16 (6) 0
Moderate 33 (14) 3 (7)
Poor 87 (33) 22 (50)
Unknown 118 (46) 19 (43)
Stage at diagnosis, n (%) 0.300
I 12 (5) 0
II 21 (9) 5 (11)
III 14 (6) 1 (2)
IV 145 (57) 30 (68)
Unknown 62 (24) 8 (18)
METex14 alterations, n (%)a 0.017
Base substitution splice donor 134 (53) 14 (32)
Indel splice acceptor 84 (33) 16 (36)
Indel splice donor 32 (13) 11 (25)
Indel noncoding adjacent splice acceptor 1 (0.4) 2 (5)
Base substitution splice acceptor 3 (1) 1 (2)
Base substitution noncoding adjacent splice acceptor 4 (1) 0
Whole exon 14 deletion 2 (0.8) 0
Concurrent MDM2 ampliﬁcation, n (%) 0.203
Yes 92 (36) 11 (25)
No 162 (64) 33 (75)
Concurrent CDK4 ampliﬁcation, n (%) 0.128
Yes 58 (23) 5 (11)
No 196 (77) 39 (89)
Concurrent EGFR ampliﬁcation, n (%) 0.643
Yes 15 (6) 4 (9)
No 239 (94) 40 (91)
Mutational burden (mutations per MB), n (%) 0.013
Low (0–5) 151 (59) 15 (34)
Intermediate low (6–10) 76 (30) 19 (43)
Intermediate high (11–20) 24 (9) 9 (20)
High (>20) 3 (1) 1 (2)
aIncludes four cases with two different METex14 alterations and one case with three different METex14 alterations (see Supplementary Table 2).
METex14, hepatocyte growth factor receptor gene exon 14 skipping; y, year; NOS, not otherwise speciﬁed; Indel: insertion/deletion; MDM2, murine double
minute 2 gene; CDK4, cyclin-dependent kinase 4 gene; MB, megabase.
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responses (ﬁve responses are ongoing), and two cases
with stable disease (Table 3 and Fig. 2). Responses to MET
TKIs were seen in patients with METex14 and concurrentMETamp, MDM2amp, or CDK4amp. One patient, a white
never-smoking woman who presented with unresectable
stage IIIB METex14-positive lung adenocarcinoma,
received neoadjuvant crizotinib for 2 months with an














Timing Response to Crizotiniba
1 AdenoCA 3028þ1_3028þ1delG Yes No Yes After
crizotinib
PR, 24 mo
2 AdenoCA D1010Y No No No Before
crizotinib
PR, 7 mo, ongoing
3 AdenoCA 3028þ1delG Yes Yes No Before
crizotinib
CR, 7 mo, ongoing
4 AdenoCA D1010H No No No Before
crizotinib
Stable disease, 4 mo, ongoing
5 AdenoCA 2888-16_2888-
3del14
Yes Yes No Before
crizotinib
PR, 10 mo, ongoing





No No No Before
crizotinib
CR, 3 mo, ongoing
8 AdenoCA 3028 þ 1G>A No No No Before
crizotinib
Unresectable to resectable and
NED after resection
aInvestigator reported.
METex14, hepatocyte growth factor receptor gene exon 14 skipping; Amp, ampliﬁcation; MDM2, murine double minute 2 gene; CDK4, cyclin-dependent kinase
4 gene; AdenoCA, adenocarcinoma; SqCC, squamous cell carcinoma; PR, partial response; mo, month; CR, complete response; NED, no evidence of disease.
September 2016 MET Exon 14–Mutated Lung Cancers 1499excellent symptomatic and radiographic response that
allowed her to undergo a complete tumor resection and
mediastinal lymph node dissection, which revealed only
extensive ﬁbrosis and no viable cancer (Fig. 3).
Discussion
In this study, we identiﬁed METex14 alterations in
298 cases (2.7%) among a large set of 11,205 lung
cancers, indicating that as a potentially actionable driver
METex14 alteration is relatively frequent. Consistent
with two retrospective studies, METex14 alterations
were enriched in a subset of lung sarcomatoid carci-
nomas included in this series (eight of 104 [7.7%]),
although the frequency of METex14 alterations in sar-
comatoid lung cancer in our series is less than the 22%
to 32% reported in recent smaller series.22,23 However,
our examination of the tissue was limited by the avail-
ability of only one hematoxylin and eosin–stained slide.
METex14 was also identiﬁed in a high frequency in
adenosquamous carcinomas (eight of 98 [8.2%]). These
data highlight the importance of CGP to identify previ-
ously underappreciated potentially druggable GAs in
these histologic subsets of NSCLC. Importantly, METex14
was identiﬁed in squamous cell carcinoma with a fre-
quency of 2.1%, which has not been previously reported.
There did not seem to be any notable difference in the
available clinical and molecular characteristics among
the major lung cancer histologic subtypes that harbor
METex14 alterations. Clinical responses to MET TKIs
have now been reported across all NSCLC histologic
subtypes, including large cell carcinoma.15 Of note, most
of the patients were elderly, with more than two-thirdsof them age 65 years or older, which is consistent with
a recent smaller study.24 Additionally, in this study
METex14 alterations were identiﬁed in patients older
than 90 years old, including in two of six patients with
the ubiquitination-deﬁcient Y1003 mutation. Hence,
screening for METex14 alterations in elderly patients
may potentially allow a subset to beneﬁt from anti–MET-
targeted therapy with fewer side effects than chemo-
therapy. Advanced age and the nonadenocarcinoma
histologic subtype should not be exclusion criteria for
screening for METex14 alterations.
The molecular alterations underpinning METex14
events are diverse, involving base substitutions and indels
at both the splice donor and acceptor sites of exon 14. In
addition, we identiﬁed two cases harboring deletion of the
whole exon 14 and 6 cases of Y1003X mutation. Y1003 is
the binding site for the ubiquitin ligase CBL, which targets
MET for degradation. Thus, Y1003 mutations are func-
tionally analogouswith the clinical sequelae ofMETex14,25
although responses in patients with Y1003X mutations to
MET-targeted therapies have not yet been reported. CGP
allows for the identiﬁcation of these diverse alterations, as
well as any additional alterations in potential codrivers.
Among 36 patients whose smoking history was
known, 25 (69%) were never-smokers, which is similar
to the proportion observed with other major driver
mutations in NSCLC.26 Although smoking status was
unknown in most of the cases in this report, patients
with never-smoking status had signiﬁcantly lower TMB
(mean ¼ 4.5 mutations per MB, median ¼ 3.3 mutations
per MB) compared with patients with a prior history of
smoking (mean ¼ 25.4 mutations per MB, median ¼ 10.4
Figure 2. Complete response to crizotinib in patient (case 3) with hepatocyte growth factor receptor gene (MET) exon 14
skipping alteration. Fludeoxyglucose F 18 positron emission tomography scan images (A) before crizotinib treatment image
and with obvious metastatic disease (B) after 6 weeks of crizotinib treatment, at which time ﬂudeoxyglucose F 18 uptake has
been diminished signiﬁcantly.
1500 Schrock et al Journal of Thoracic Oncology Vol. 11 No. 9mutations per MB) (p ¼ 0.046). On the basis of the
observation that most of the patients with METex14 had
a low (56%) or low intermediate (32%) mutation
burden, we predict that most would be never-smokers.
Concurrent METamp was identiﬁed in 15% of
METex14 cases. We did not observe a signiﬁcantFigure 3. Pre–crizotinib treatment and post–crizotinib treatmen
from an adenocarcinoma harboring hepatocyte growth factor
Before crizotinib low-(40X) (A) and high-magniﬁcation (200X) (B
in a mediastinal lymph node showing retraction artifact seen in
of neoadjuvant crizotinib low-(40X) (C) and high-magniﬁcation
primary lung tumor.association between METamp and stage IV disease (p ¼
0.42), as was recently reported on the basis of an
analysis of 28 patients with METex14 adenocarcinoma.24
The caveat is that 23% of the patients in this series had
an unknown stage; thus, this correlation between stage
and METamp will have to be investigated further.t hematoxylin and eosin stain from a mediastinal lymph node
receptor gene (MET) exon 14 skipping alteration. (A and B)
) hematoxylin and eosin–stained images of a metastatic lesion
tumors with micropapillary features. (C and D) After 2 months
(100X) (D) images showing extensive ﬁbrosis in the resected
September 2016 MET Exon 14–Mutated Lung Cancers 1501Concurrent MDM2amp was the most common ampliﬁ-
cation identiﬁed in our series of METex14 cases, and it
has been identiﬁed as an oncogenic event in diverse
tumor types acting through negative regulation of p53
function through ubiquination.27,28 CBL is the ubiquitin
ligase implicated as being primarily responsible for
ubiquitination of MET due to the presence of a tyrosine
kinase binding domain.29 While METex14 protein lacks
a tyrosine kinase binding domain, it is unknown
whether MDM2amp is a compensatory mechanism to
increase ubiquitination of MET through a different
portion of MET protein or an event independent of
METex14 alterations. Patients with METex14 both with
and without METamp or MDM2amp in this study and
others have responded to MET TKIs.15 Whether overall
there is a differential response to MET TKIs according to
METamp or MDM2amp status in the context of METex14
alterations needs to be investigated in a larger series of
patients or clinical trials, especially given that there
appears to be a signiﬁcant difference in the TMB by
METamp status. Conversely, it will be important to
investigate the frequency of METex14 alterations among
cases with de novo METamp so as to truly identify the
biology of METamp and METex14 alterations as separate
driver mutations in NSCLC.
Lastly, we report eight previously unpublished
METex14 patients who responded to MET TKIs. For the
ﬁrst time, both pre–crizotinib treatment and post–
crizotinib treatment tumor histologic information was
available for one patient who demonstrated only exten-
sive ﬁbrosis after crizotinib treatment. MET is involved
in the mesenchymal-to-epithelial transition, and the
extensive ﬁbrosis as opposed to apoptosis or necrosis
may be related to the loss of this MET driver event.
These data, together with previously published case re-
ports/series, provide strong preliminary evidence that
METex14 alterations are targetable driver mutations in
lung cancer. Several phase 2 trials of MET TKIs targeting
METex14 alterations speciﬁcally are now ongoing, and
the results from these prospective trials will be neces-
sary to determine the response rate in this population.
The high response rate to MET TKIs across patients with
METex14 alterations indicates that comprehensive
genomic proﬁling in the course of clinical care is
imperative to identify all possible molecular changes
underpinning MET activation so that these patients can
beneﬁt from treatment with MET TKIs.
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